CALT
NASDAQCalliditas Therapeutics AB
Latest news
25 items- SECSEC Form 15F-12B filed by Calliditas Therapeutics AB15F-12B - Calliditas Therapeutics AB (0001795579) (Filer)
- 13D/GAmendment: SEC Form SC 13D/A filed by Calliditas Therapeutics ABSC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)
- SECSEC Form 25-NSE filed by Calliditas Therapeutics AB25-NSE - Calliditas Therapeutics AB (0001795579) (Subject)
- SECAmendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics ABSC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)
- 13D/GAmendment: SEC Form SC 13D/A filed by Calliditas Therapeutics ABSC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)
- SECSEC Form EFFECT filed by Calliditas Therapeutics ABEFFECT - Calliditas Therapeutics AB (0001795579) (Filer)
- SECAmendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics ABSC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)
- PRDelisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmSTOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com The information was sent for publication, through the agency of the contact person set out above, on September 16, 2024 at 15:30 CET. About Calliditas Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan in
- SECSEC Form 25 filed by Calliditas Therapeutics AB25 - Calliditas Therapeutics AB (0001795579) (Filer)
- SECSEC Form S-8 POS filed by Calliditas Therapeutics ABS-8 POS - Calliditas Therapeutics AB (0001795579) (Filer)
- SECSEC Form S-8 POS filed by Calliditas Therapeutics ABS-8 POS - Calliditas Therapeutics AB (0001795579) (Filer)
- SECSEC Form POS AM filed by Calliditas Therapeutics ABPOS AM - Calliditas Therapeutics AB (0001795579) (Filer)
- 13D/GAmendment: SEC Form SC 13G/A filed by Calliditas Therapeutics ABSC 13G/A - Calliditas Therapeutics AB (0001795579) (Subject)
- 13D/GAmendment: SEC Form SC 13D/A filed by Calliditas Therapeutics ABSC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)
- 13D/GAmendment: SEC Form SC 13D/A filed by Calliditas Therapeutics ABSC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)
- SECAmendment: SEC Form SC 14D9/A filed by Calliditas Therapeutics ABSC 14D9/A - Calliditas Therapeutics AB (0001795579) (Subject)
- SECSEC Form 6-K filed by Calliditas Therapeutics AB6-K - Calliditas Therapeutics AB (0001795579) (Filer)
- SECAmendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics ABSC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)
- PRNotice of extraordinary meeting of Calliditas Therapeutics AB (publ)STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the extraordinary general meeting on Monday 30 September 2024 at 12:00 p.m. CEST at Advokatfirman Vinge's premises on Smålandsgatan 20, SE-111 46, Stockholm, Sweden. Registration starts at 11:30 a.m. CEST. Background Asahi Kasei Corporation ("Asahi Kasei"), which has announced that the public offer made regarding the company's shares has been accepted to such extent that Asahi Kasei becomes the owner of more than 90 per cent of the shares and votes in the company, has requested the board of dire
- PRCalliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiSTOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (NASDAQ:CALT) ("Calliditas" or the "Company"), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas unconditional and intends to initiate compulsory redemption of the remaining shares of the Company, the Board of Directors of Calliditas has resolved, in accordance with a request from Asahi Kasei, to take certain corporate actions. Delisting of Common Shares and Delisting, Deregistration, and Termination of ADS Program In light
- SECSEC Form 6-K filed by Calliditas Therapeutics AB6-K - Calliditas Therapeutics AB (0001795579) (Filer)
- SECAmendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics ABSC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)
- PRCalliditas Interim Report January to June 2024STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.Operating loss amounted to SEK 31.5 million and SEK 75.2 million for the three months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive prog
- PRInvitation to the presentation of Calliditas's interim report January - June 2024STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the second quarter, April - June 2024 will be published in Swedish and English on Tuesday 13 August 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast: https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024 To participate via conference call please register via this link: https://conference.financialhearings.com/tel
- SECAmendment: SEC Form SC 14D9/A filed by Calliditas Therapeutics ABSC 14D9/A - Calliditas Therapeutics AB (0001795579) (Subject)
CALT FAQ
7 questionsWhat does Calliditas Therapeutics AB do?
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) was founded in 2004 and is headquartered in Stockholm, Sweden.Where does CALT stock trade?
Calliditas Therapeutics AB (CALT) is listed on NASDAQ.What sector and industry is CALT in?
Calliditas Therapeutics AB operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Calliditas Therapeutics AB go public?
Calliditas Therapeutics AB (CALT) completed its IPO in 2020.What are analysts saying about CALT?
Calliditas Therapeutics AB has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2023-06-20. Recent price targets cluster around $1800.00.What companies are similar to CALT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CALT side-by-side with any of them on Quantisnow.How can I track CALT on Quantisnow?
Quantisnow aggregates Calliditas Therapeutics AB's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CALT to receive live email and push alerts on every new disclosure.